The interleukin-1 gene cluster is a key regulator in a number of chronic disease processes. We explored the linkage between nine polymorphic loci in the IL1R1 promoter, eight in the IL1A-IL1B-IL1RN gene complex, and their association with osteoarthritis (OA), a common complex disease associated with low-level inflammation. Using 195 healthy controls, we identified eight novel polymorphisms in the IL1R1 exon 1A region. We found limited LD between IL1R1 and the IL1A-IL1B-IL1RN cluster, although LD within these two individual groups was high. To test association with knee OA, we genotyped 141 patients from Bristol (UK) at the 17 loci. IL1R1 promoter haplotypes showed no association with disease. However, within the IL1A-IL1B-IL1RN complex, we identified a common haplotype conferring a four-fold risk of OA (P ¼ 0.00043; P c ¼ 0.0043) and one IL1B-IL1RN haplotype conferring a four-fold reduced risk (P ¼ 0.0036; P c ¼ 0.029). To replicate these associations, we subsequently examined 163 knee OA patients from London. Here, the effects of the haplotypes were confirmed: the risk IL1A-IL1B-IL1RN haplotype conferred a two-fold risk of OA (P ¼ 0.02), and the protective IL1B-IL1RN haplotype conferred a fivefold reduced risk of OA (P ¼ 0.0000008). These results may help to explain the genome-wide scan linkage data and functional observations concerning association between IL-1 and OA.
Introduction
The regulation of the immune system relies on the complex interaction within the cytokine network, where the products of cytokine genes and their respective receptor genes must be finely tuned to maintain an optimal physiological environment. The interleukin-1 (IL-1) system epitomises the highly regulated mechanism required for this to be achieved. Several related gene products interact with each other to adjust the response according to cellular requirements. IL-1 signalling via the interleukin-1 receptor type I (IL-1RI) is an important pathway in the inflammatory process, innate immunity and the immune response. 1 Its effects are various, including the stimulation of fibroblast and keratinocyte proliferation, cartilage breakdown, angiogenesis and increased production of acute phase response proteins by the liver. 2 These physiological effects are mediated at the molecular level by the activation of JNK and p38 MAP kinases, and consequent upregulation of genes via the transcription factors NF-kB, AP-1 and C/EBPb 3 The products of the IL-1 gene cluster are thought to play a role in a number of diseases, one of which is osteoarthritis (OA). This disease affects an estimated 5 million people in the UK 4 and over 16 million in the US, 5 and is characterised by focal loss of cartilage matrix in the affected joints. IL-1 is thought to contribute to this loss by stimulating chondrocytes to produce cartilage matrix degrading enzymes. In support of this contention, a strong correlation exists between specific cleavage of the aggrecan core protein at the Glu373-Ala374 bond and the release of aggrecan catabolites in response to IL-1: 6 fragments bearing this epitope are found in synovial fluids of OA patients. 7 In addition, cells from OA synovium produce more IL-1b than normal synovium, 8, 9 and similarly, chondrocytes for OA cartilage secrete both IL-1a and IL-1b unlike normal chondrocytes. 10, 11 It is also known that OA cartilage explants are more susceptible to the effects of IL-1 than similar explants from nonarthritic cartilage 12 and that this susceptibility is related to the expression of IL-1 receptor types 1 and 2 on chondrocytes. 13 A further line of evidence comes from genetic studies. First-degree relatives of patients with generalised radiologic OA are twice as likely to develop the disease as people in the general population, 14 and monozygotic twins are significantly more concordant for hand and knee osteoarthritis than dizygotic twins. 15 Thus, a genetic predisposition to OA exists. Interestingly, some genomewide scans for predisposing genetic loci to OA reveal potential linkage with the IL-1 gene cluster on chromosome 2. 16, 17 Taken together, these results implicate both IL-1 and its receptors in the progression of OA in at least some patients, and suggest that a search to determine if genes in the IL-1 cluster are associated with OA is justified.
IL-1 acts through its signalling receptor, IL-1 receptor type 1 (IL-1RI), and the degree of expression of this receptor influences the response of cells to IL-1. 18 The cloning and characterisation of the two IL-1 receptors (type 1 and 2) 19 has revealed the IL-1 receptor type 2 to function as an IL-1 binding protein that acts as a competitive decoy, lacking the cytoplasmic residues necessary for intracellular signalling. 20 Three structurally related ligands can bind to the IL-1 receptors: IL-1a and the more abundant IL-1b functioning as agonists, and IL1Ra as an antagonist that results in no intracellular signalling.
IL-1a, IL-1b, IL-1Ra and the two IL-1 receptors, type 1 (IL-1RI) and type 2 (IL-1RII), are encoded by a cluster of genes (IL1A, IL1B, IL1RN, IL1R1 and IL1R2, respectively) situated on chromosome 2 ( Figure 1a) . Recently, six new IL-1 family genes have been mapped between IL1B and IL1RN: IL1F7, IL1F9, IL1F6, IL1F8, IL1F5 and IL1F10. 21, 22 These genes share the same common ancestor as IL-1 and IL-18, with regions of amino acid and genetic homology, but their function is currently uncharacterised. The IL1A, IL1B and IL1RN genes have been extensively examined for polymorphic nucleotide residues: the literature on these polymorphisms, their effect on gene expression, and their influence on human diseases has been reviewed. [23] [24] [25] The IL1R1 gene (Figure 1 ) contains 14 exons and has three distinct promoters, generating three alternative transcripts with differing 5 0 -untranslated regions, derived from exons 1A, 1B or 1C. 26 Since the levels of transcription of certain cytokine genes are influenced by polymorphic nucleotides in the promoter sequences, 23 and IL-1RI is expressed on a wide variety of cells subjected to different evolutionary pressures (including those from microorganisms), we predicted that the promoter region of IL1RI should be highly polymorphic. Indeed, we, and others, have previously reported nucleotide sequence polymorphism in the promoter region spanning introns 1A-1C. [27] [28] [29] [30] [31] In the present report, we describe the identification and characterisation of a further eight novel polymorphisms in the IL1R1 promoter. Recently, a number of reports have indicated that polymorphic IL-1 haplotypes or extended haplotypes, as opposed to single locus polymorphisms, may provide better genetic markers of transcriptional activity and disease association, 32 in particular with the complex nature of the IL-1 agonist/antagonist relationship and the two IL-1 receptors. 33 To begin to address this concept with respect to osteoarthritis, this report examines the extent of linkage disequilibrium and the occurrence of haplotypes and extended haplotypes within the IL1R1-IL1A-IL1B-IL1RN region.
Results
Novel polymorphisms in the IL1R1 exon 1A promoter, exon 1A and intron 1A Sequencing of amplicons showing PCR-SSCP variation revealed eight novel polymorphisms (rows 1-8, Table 1 ; Figure 2 ). We were also able to confirm and further characterise a previously described polymorphism in exon 1A at position þ 103 C4T (dbSNP, rs1019296). The two contiguous exon polymorphisms at positions þ 102 G4A and þ 103 C4T formed only three haplotypes from a possible four, with the genotypic combinations GT, GC and AT at the respective positions. These were considered as a single polymorphism with three alleles for the purposes of haplotype analysis, where GT ¼allele 1, GC ¼ allele 2 and AT ¼allele 3 ( Table 1 ). Further details of the polymorphisms identified in the study, and used in the subsequent haplotype analyses, are given in Table 1 .
Linkage disequilibrium in the IL1R1-IL1A-IL1B-IL1RN region The patient and control cohorts were genotyped for nine commonly occurring polymorphisms in the IL1R1 gene ( Figure 1c ) and a series of eight polymorphisms previously described in IL1A, IL1B and IL1RN genes ( Table 1) . Pairwise linkage disequilibrium (LD) was determined for all 17 loci in 195 control DNAs ( Figure 3 ). This revealed a high level of LD between the polymorphic loci in IL1R1. Similarly, there was considerable intragenic and intergenic LD between polymorphisms in the IL1A-IL1B-IL1RN complex, particularly between the IL1A IVS4 TTA repeat, the IL1RN IVS2 86 bp VNTR and the IL1RN IVS3 þ 59 loci. Although the LD between the IL1A-IL1B-IL1RN complex and the IL1R1 promoter polymorphisms is much reduced, there are loci which show a significant degree of LD, for example three IL1R1 loci (Exon 1A þ 102/103 haplotype, IVS1A þ 463-464 insT and IVS1A þ 36995) with IL1B and IL1RN; and two IL1R1 loci (IVS1A þ 783 and IVS1A þ 35884) with IL1A IVS4 (TTA)n.
Haplotypes in the IL1R1 promoter and IL1A-IL1B-IL1RN complex and association with OA Genotypes at the 17 polymorphic loci (Table 1) represented a total of 95 IL1R1-IL1A-IL1B-IL1RN haplotypes in the control subjects. In view of the overall weak LD between the IL1R1 promoter and the IL1A-IL1B-IL1RN complex, separate haplotype analyses were conducted. The nine IL1R1 promoter polymorphisms revealed a total of 33 haplotypes in controls and patients from Bristol and London with knee OA. A total of 299 of the 304 patients were included in the IL1R1 haplotype study: the five remaining individuals were excluded due to incomplete genotyping data. Table 2 shows details of the five haplotypes with a frequency of 0.05 or more in either controls or patients (haplotype nomenclature is explained in Table 2 footnote). There was no significant difference between any of the IL1R1 promoter haplotype frequencies in controls or patients.
A parallel analysis of the eight polymorphisms in the IL1A-IL1B-IL1RN complex revealed a total of 37 haplotypes in controls and knee OA patients. Table 3 shows details of the nine haplotypes with a frequency of 0.05 or higher, in either controls or patients (haplotype nomenclature is explained in Table 3 footnote).
The Bristol knee OA cohort was examined first. Here, we found one haplotype (2C-CTG-1TT) was significantly more frequent in patients with knee OA than in controls (OR ¼ 3.93, CI ¼ 1.68-9.25, P ¼ 0.00043, P c ¼ 0.0043). When sexes were analysed separately, the association remained significant (males, P ¼ 0.0069; females, P ¼ 0.0037). Further scrutiny of these data indicated that there may be a protective haplotype, masked by the inclusion of the IL1A genotypes. We thus conducted a further analysis of the six polymorphisms within the IL1B-IL1RN region. This revealed a total of 20 haplotypes in controls and patients. Table 4 shows details of the seven haplotypes with a frequency of 0.05 or higher, in either controls or patients (haplotype nomenclature is explained in Table 4 footnote). One haplotype (CCA-1TT) was significantly less frequent in patients than in controls (OR ¼ 0.37, CI ¼ 0.18-0.77, P ¼ 0.0036, P c ¼ 0.029), representing a putative protective factor against knee OA. When sexes were analysed as subgroups, the trends were the same: the significance of the association reduced in males (P ¼ 0.051), although the association with females remained significant (P ¼ 0.014).
To verify these associations in a different population, we duplicated the analyses in a knee OA patient cohort from London. The putative risk haplotype in the IL1A-IL1B-IL1RN region (2C-CTG-1TT) was also significantly increased in this OA cohort (OR ¼ 2.32, CI ¼ 1.05-5.08, P ¼ 0.02; Table 3 ). When sexes were analysed separately, the association remained significant (males, P ¼ 0.00036; females, P ¼ 0.038). A duplicate analysis of the IL1B-IL1RN region in the London OA cohort showed that the frequency of the putative protective haplotype was also significantly reduced (OR ¼ 0.19, CI ¼ 0.09-0.40, P ¼ 0.0000008; Table 4 ). As observed with the Bristol cohort, the statistical significance was lost in males, but was still highly significant in females (P ¼ 0.0000008), although the numbers (n ¼ 38) of males in the London cohort was low.
Discussion IL-1 ligand-receptor signalling is a highly sensitive immune process, where even small changes in gene expression may result in widespread changes to the cell's environment. Indeed, fewer than 10 ligand-occupied IL-1 receptors are sufficient to transduce a strong intracellular signal.
2 IL-1 is a highly proinflammatory cytokine and the levels of signalling are greatly increased in many disorders, including autoimmune diseases. Recent work on IL-1-associated disorders has led researchers to search for predisposing loci within the highly polymorphic IL1R1-IL1A-IL1B-IL1RN gene cluster that may help to pinpoint genetic markers of disease susceptibility, severity or outcome. Impetus for examination of these loci has been further provided by results of genome-wide scans for susceptibility loci. 16, 17 Much of the research to date has focused on individual polymorphisms or small numbers of polymorphisms in single genes. However, this approach may be oversimplistic due to the complex interaction of the ligands and receptors involved in the transduction and inhibition of IL-1 signalling, and because of linkage disequilibrium within the genes encoding the ligands and receptors. Since the immunopathology of osteoarthritis includes induction of high levels of IL-1 in the synovial fluid, we hypothesised that haplotype or extended haplotype analysis across a region encompassing the IL1R1, IL1A, IL1B and IL1RN genes might indicate haplotypic markers of disease susceptibility or severity which individual genotypic markers may fail to reveal.
From analysis of 17 polymorphic loci, we identified 95 extended IL1R1-IL1A-IL1B-IL1RN haplotypes. These data also revealed that strong LD exists between polymorphic loci in the IL1R1 promoter and in the IL1A-IL1B-IL1RN complex, but that between these two regions, considerably less LD exists. Allelic or haplotypic polymorphism within the IL1R1 promoter might involve alteration in transcription factor binding sites and thus exert a regulatory influence on receptor expression, thereby contributing to the aetiology or immunopathology of knee osteoarthritis. However, we found no association between promoter haplotypes in the IL1R1 gene and knee osteoarthritis. TRANSFAC 6.0 analysis (http://www.gene-regulation.com/pub/databases.html# transfac) of the IL1R1 promoter polymorphism at position À227 upstream of exon 1A, revealed a potential NF-kB binding site motif. We tested the potential functional significance of this polymorphism using two reporter gene assays. However, no differences were observed in expression or response to IL-1 induction in À227G and À227A clones, either in a pGL3-SV40 luciferase reporter system, or in a lentiviral-GFP vector.
In contrast to the IL1R1 results, we identified an extended IL1A-IL1B-IL1RN risk haplotype (2C-CTG-1TT), which was significantly more frequent in patients with knee osteoarthritis. In an analysis of IL1B-IL1RN region haplotypes, one of these (CCA-1TT) was associated with a significant protective effect against knee osteoarthritis. In order to reconcile our extended haplotype approach with potential functional differences, we examined individual polymorphisms within the haplotypes which have been previously associated with regulation of expression. The IL1B-IL1RN CCA-1TT protective haplotype differed from the risk haplotype in the genotypes at positions À31 and À511 in the IL1B gene. These two polymorphisms are in significant LD (see Figure 3) . The IL1B À31T allele creates a TATA box, which has been shown to bind TATA-binding protein (TBP), 41 whereas the IL1B À31C allele does not. It has been suggested that the strongly linked IL1B À31T and the IL1B À511G alleles may be associated with higher T on IL1B coding strand.
Interleukin-1 gene cluster associated with OA AJP Smith et al levels of gene expression than the IL1B À31C and IL1B À511A alleles: 41, 42 we are currently investigating this possibility. This could represent a partial functional explanation for the association of the risk haplotype (2C-CTG-1TT) with knee OA, since this haplotype contains the IL1B À31T and IL1B À511G genotypes, is TATA-box positive, and may be associated with highlevel expression of IL-1b (a potent mediator of inflammation in OA joints). In contrast, the protective haplotype (CCA-1TT) contains the IL1B À31C genotype, is TATA-box negative, and is associated with lower levels of IL-1b production.
The importance of examining extended haplotypes of the IL-1 gene cluster is made clear by this study. We identified no association of the individual IL1B polymorphisms with osteoarthritis, but statistically significant associations when haplotypic analysis was conducted. The level of IL-1Ra expression will undoubt- chr2:102346067  102346081  102346099 102346108  Allele GenBank  AFL  2  AC007271  309  GTGTGTGTGTGTGTGT--ATGTATGTGTGTGTGTGT--GGGGGGGGGTGTG…  1  AF469755  306  GTGTGTGTGTGTGTGT--ATGTATGTGTGTGTGT----GGGGGGGG-TGTG…  3  AF469756  313  GTGTGTGTGTGTGTGTGTATGTATGTGTGTGTGTGTGTGGGGGGG--TGTG…  < Figure 2 Nucleotide sequence alignment of alleles within the complex microsatellite region of IL1R1 IVS1A. Alleles were designated numerically according to amplified fragment length (AFL) in base pairs: for details of the PCR primers and conditions used see Table 1 and text. Polymorphisms with respect to the reference allele 2 (GenBank AC007271) are: allele 1 ¼ 102346097-8 del GT, 102346108 del G and allele 3 ¼ 102346081 insGT, 102346099 insGT, 102346107-8 del GG. Chromosome 2 locations (top line) correspond to the UCSC July 2003 assembly (http://genome.cse.ucsc.edu/). Allele frequencies are shown in Table 1 . Figure 3 Linkage disequilibrium analysis of polymorphisms in the IL1R1, IL1A, IL1B and IL1RN genes. P-values of the Lewontin's |D 0 | coefficient for each two-way comparison are as shown in the key; ns, not significant.
Interleukin-1 gene cluster associated with OA AJP Smith et al edly have a major impact on a cell's responsiveness to IL1a and IL-1b. Both the identified risk and protective extended haplotypes possess the IL1RN '1TT' haplotype, which includes the VNTR allele 1, implicated to express IL-1Ra at lower levels than VNTR allele 2. 43 It is believed, however, that IL-1Ra expression is also influenced by IL1B genotype: previous research has identified association between the IL1B À511, IL1B exon 5 þ 14 and IL1RN VNTR genotypes and their combined influence on the level of IL-1Ra plasma levels. 33 One logical explanation for our findings is that in the risk haplotype population, the IL1A and IL1B alleles may not only lead to high IL-1b Interleukin-1 gene cluster associated with OA AJP Smith et al production, but may also confer a lower level of IL-1Ra expression: for the protective haplotype, the opposite might be the case. This might explain the observation in some individuals, of both higher levels of IL-1b found in OA synovium, and the increased susceptibility of OA cartilage to IL-1b, due to the concurrent reduction of IL1Ra expression. Our results indicate potential IL1A-IL1B-IL1RN extended haplotypes associated with susceptibility to OA. This could help to explain previous reports of linkage from some groups between markers in this region and OA in genome-wide scans. 16, 17 However, it should be stressed that the disease is a multigenic disorder and our data identifies only one of the susceptibility loci involved, each of which represent an as yet unknown proportion of the overall genetic influence.
Methods

Patients and controls
Osteoarthritis patients (n ¼ 304) were studied from two UK centres: Bristol (n ¼ 141, 65 male and 76 female Caucasians: mean age ¼ 62; median age ¼ 63); and London (n ¼ 163, 38 male and 125 female Caucasians: mean age ¼ 71; median age ¼ 71). All patients had osteoarthritis as defined by the ACR criteria with at least grade 2 radiological change. Control subjects were 195 (97 male and 98 female) unrelated healthy Caucasian volunteer blood donors from South West England. Informed consent was obtained with appropriate local ethics committee approval. Genomic DNA was isolated from peripheral blood leucocytes using a salting-out procedure. 44 Identification of novel polymorphisms in the IL1R1 exon 1A region PCR-SSCP analysis 45 was used to determine the extent of nucleotide sequence polymorphism around the first untranslated exon of the human IL1R1 exon, using a large series of overlapping PCR primers derived from a published IL1R1 sequence (GenBank AC007271), designed to produce amplicons of approximately 250 bp, overlapping each other by 20-50 bp. DNAs from 195 healthy controls (see above) were screened for polymorphism, within the region 2 kb upstream to 4 kb downstream of the exon 1A transcription start site (Figure 1c) . PCR conditions were essentially as described below. Following amplification, PCR-SSCP analysis was performed using polyacrylamide gel electrophoresis (PAGE) as described 45 in 12% nondenaturing polyacrylamide gels (Protogel, National Diagnostics, Atlanta, GA, USA) containing 1 Â TBE buffer. Electrophoresis was carried out at 300 V for 140 min on a triple-wide minigel system (CBS Scientific Company Inc., Del Mar, USA). DNA was visualised by staining for 10 min with ethidium bromide (0.5 mg/ml in 1 Â TBE buffer) and gels were imaged using a Kodak EDAS 120 digital camera. Nucleotide sequencing of SSCP variants was performed by automated nucleotide sequencing on an ABI 310 sequencer (Perkin-Elmer, Norwalk, USA).
SNP and VNTR genotyping
For each polymorphic locus to be analysed, PCR amplifications were set up in a total volume of 20 ml containing 200 ng genomic DNA, 0.1 U Taq polymerase (Abgene, Epsom, Surrey, UK), 0.05 mM of each PCR primer (Table 1) RFLP analysis was carried out for the IL1R1 SNPs where appropriate (Table 1 ). The restriction endonucleases, MspI, PstI, HinfI, HincII, AluI, FokI, NlaIII and HhaI (New England Biolabs Inc., MD, USA), were used according to the manufacturer's instructions. Briefly, 4 U of enzyme were used per 10 ml amplified DNA, and incubated at 371C for 6 h. Following digestion, DNA samples were electrophoresed in 15% nondenaturing polyacrylamide gels for 60 min and imaged on a UV transilluminator using a Kodak EDAS 120 digital camera. Analysis of repeat sequences was carried out by PAGE using 12% Accugel (National Diagnostics, Atlanta, GA, USA) for 50 min (IL1RN IVS2 86 bp VNTR, IL1A IVS4 TTA repeat, and 100 min (IL1R1 IVS1A complex microsatellite) (see Table 1 ). For the IL1R1 -227 A4G SNP, induced heteroduplex generator (IHG) analysis was used, incorporating an [AAAA] insertion adjacent to the polymorphic site. 34 The same method was used to identify the polymorphisms IL1A -889 C4T, IL1B Exon 5 þ 14 C4T, IL1B -31 C4T, IL1B -511 G4A, IL1RN IVS3 þ 59 T4C and IL1RN Exon 4 þ 72 T4C (Table 1) .
Linkage disequilibrium, haplotype frequency and disease association analysis Allele frequencies were estimated by gene counting and potential deviation in Hardy-Weinberg equilibrium was tested using the w 2 test with 1df. For the control population Arlequin version 2.000 46 was used to determine pairwise linkage disequilibrium (LD), expressed as Lewontin's |D 0 | coefficient-statistical significance of the P-value was defined at the 5% level.
Haplotypes were constructed from genotypic data using the PHASE 2.0 software platform. 47, 48 Haplotypes with an observed frequency of less than 0.05 were analysed as a combined group. To identify potential risk or protective haplotypes, haplotype frequency comparisons between control and OA patients were performed using haplotypic odds ratios (OR) with Cornfield 95% confidence intervals (CI). For all analyses, the reference haplotype was that which occurred most frequently. 49 Pearson's w 2 test or Fisher's exact test were used to determine uncorrected P-values and corrections were made for multiple comparisons (p c ) where appropriate.
